Axcella to Present at the 28th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Axcella, a biotechnology company pioneering transformative medicines for
patients with conditions where disrupted amino acid biology plays a
critical role, announced today that Robert Connelly, President and Chief
Executive Officer, will present a company overview at the 28th Annual
Piper Jaffray Healthcare Conference in New York, N.Y. The presentation
will take place November 30, 2016, at 3:10 p.m. EST.

About Axcella

Axcella is pioneering revolutionary new medicines with a focus on amino
acid homeostasis. The company has identified more than 2,000 diseases
with amino acid imbalances and developed a systems pharmacology approach
to restore health at the cellular level. Axcella’s proprietary platform
is clinically validated across several indication areas, with
clinical-stage candidates in metabolic (liver, muscle) and
neurodegenerative conditions. Axcella is led by a team with a strong
track record of leaving a lasting impact on the therapeutic landscape
through the development of novel products. The company was founded by
VentureLabs, the Innovation Foundry at Flagship Ventures, and has
received additional funding from Fidelity Research & Management Group,
Gurnet Point Capital and Nestlé Health Science. Axcella is based in
Cambridge, Mass. For more information, visit www.axcellahealth.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005013/en/